Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Nasopharyngeal Carcinoma 6Uterine Cervical Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Esophageal Squamous Cell Carcinoma 4Pancreatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Nasopharyngeal Neoplasms 2Uterine Cervical Dysplasia 1Solid Tumors 1Solid Tumor 1Recurrence 1Oropharyngeal Neoplasms 1Neoplasms 1Nasopharyngeal Diseases 1NSCLC 1Meningeal Carcinomatosis 1Lung Neoplasms 1Locally Advanced Rectal Cancer 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1HCC 1Esophageal Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Childhood Brain Stem Neoplasm 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Advanced Pancreatic Cancer 1Advanced Colorectal Cancer 1Advanced Cancer 1

Interventions

Cisplatin 38Carboplatin 28Gemcitabine 23Docetaxel 20Radiotherapy 18Etoposide 15Paclitaxel 13Erlotinib Hydrochloride 13Vinorelbine 11Drug Therapy 11pembrolizumab 9aumolertinib 9apatinib 9Pemetrexed 9Gefitinib 9osimertinib 7endostar protein 7Thoracic Surgery, Video-Assisted 7Blood Specimen Collection 7camrelizumab 6anlotinib 6Vinblastine 6Surgical Procedures, Operative 6sintilimab 5Radiosurgery 5Fluorodeoxyglucose F18 5Cyclophosphamide 5Bevacizumab 5durvalumab 4Mitomycin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lung Neoplasms × nimotuzumab × Clear all
NCT04833205 2021-04-20

Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer

Hebei Medical University

Phase 2 Unknown
30 enrolled
CNSThoracic

Lung Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡